This strategy combats tumour heterogeneity, resistance mechanisms, and depth/duration of response while extending the spectrum of treatments to encompass HR+ and HER2-low disease, paving the way for personalized, multi-modal, and adaptive therapies in early-stage as well as metastatic settings [25]. This evidence concerns the gene ERBB2 and neoplasm.